SCHEMBL858995

SCHEMBL858995

CC(C)(C)NS(=O)(=O)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
LMNA P02545 1/20 0.54
HPGD P15428 1/20 0.54
RAB9A P51151 1/20 0.54
NAPRT Q6XQN6 1/20 0.52
ALDH1A1 P00352 4/20 0.51
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
POLB P06746 2/20 0.48
HTT P42858 1/20 0.48
SLC40A1 Q9NP59 2/20 0.47
GLO1 Q04760 1/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30530541 1.00 MAPT (0.54) MAPTSMN1; SMN2KMT2AKDM4EMEN1
SCHEMBL21960087 0.89 NAPRT (0.52) MAPTSMN1; SMN2KMT2AKDM4EMEN1
SCHEMBL579072 0.83 KMT2A (0.50) MAPTSMN1; SMN2KMT2AMEN1NAPRT
SCHEMBL28888409 0.82 SLC1A3 (0.50) MAPTSMN1; SMN2KMT2ANAPRTALDH1A1
SCHEMBL486015 0.82 KMT2A (0.55) MAPTKMT2AMEN1NAPRTKEAP1
SCHEMBL2227366 0.79 NAPRT (0.57) MAPTSMN1; SMN2KMT2ANAPRTALDH1A1
SCHEMBL30338836 0.79 NAPRT (0.57) MAPTSMN1; SMN2KMT2ANAPRTALDH1A1
SCHEMBL21960093 0.79 ALDH1A1 (0.54) MAPTSMN1; SMN2KMT2ALMNAHPGD
SCHEMBL13605865 0.79 NAMPT (0.57) MAPTSMN1; SMN2KMT2ANAPRTALDH1A1
SCHEMBL25767760 0.79 MAPT (0.42) MAPTSMN1; SMN2KMT2ALMNANAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014106800-A2 SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-07-10 WO claimed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
CN-108367079-B Aggregated microparticles for therapy 灰色视觉公司 2022-11-22 CN disclosed
US-9938301-B2 Dihydropyrimido fused ring derivative as HBV inhibitor QILU PHARMACEUTICAL CO., LTD. (CN) 2018-04-10 US disclosed
US-9938301-B2 Dihydropyrimido fused ring derivative as HBV inhibitor QILU PHARMACEUTICAL CO., LTD. (CN) 2018-04-10 US disclosed
US-20170197986-A1 DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2017-07-13 US disclosed
US-20170197986-A1 DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2017-07-13 US disclosed
CN-106459063-A MERKs-specific pyrimidine compounds 北卡罗来纳-查佩尔山大学 2017-02-22 CN disclosed
US-9139609-B2 C-4″ position substituted macrolide derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-22 US disclosed
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-02-13 US disclosed
EP-2432782-A1 METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS CELLZOME AG (DE) 2012-03-28 EP disclosed
WO-2010133318-A1 METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS CELLZOME AG (DE) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 MAPT 4649/4885SMN1; SMN2 285/4885KMT2A 742/4885
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MRPL21, MRPS34, MRPL37 MAPT 3750/4885SMN1; SMN2 1688/4885KMT2A 3170/4885
US-20170197986-A1 DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR TMBIM6, HAVCR2, HDGF MAPT 2073/4885SMN1; SMN2 4825/4885KMT2A 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.